Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...
Biogen and Eisai also touted an increase in prescribers and eligible patients for Leqembi. According to Eisai’s presentation, there are currently 10,000 patients in the U.S. who are eligible for ...
A downtrend has been apparent in Biogen Inc. (BIIB) lately with too much selling pressure. The stock has declined 6.4% over the past four weeks. However, given the fact that it is now in oversold ...
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a Biologics License ...
Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback